Module 6: Project- Signature Assessment

(Pfizer and Warner-Lambert)

ALY6130 – Risk Management, Northeastern University, Boston

Professor Daya Rudhramoorthi

CRN: 20517

03/31/2023

Submitted by: Abhinav Jain

Introduction

Pfizer is a multinational pharmaceutical firm that focuses on the research and development of novel medicines, vaccines, and consumer healthcare products. The firm was started in Brooklyn, New York in 1849 and has since evolved to become one of the world's greatest pharmaceutical corporations.

Pfizer's medication portfolio comprises therapies for a variety of ailments, including cancer, immunology, uncommon disorders, and cardiovascular diseases. Moreover, Pfizer is a prominent vaccine maker, including the COVID-19 vaccine created in collaboration with BioNTech.

Pfizer is committed to R&D, investing extensively in clinical trials and forming relationships with academic institutions and other industrial players. The corporation operates in over 150 countries and employs over 80,000 employees globally.

Pfizer has been involved in several high-profile mergers and acquisitions in recent years, including the purchase of Hospira, a leading provider of injectable drugs and infusion technologies, and the merger with Allergan, a global pharmaceutical company specializing in aesthetic medicine and ophthalmology.

Warner-Lambert was a pharmaceutical and consumer goods company that was formed in 1955 through the merger of Warner-Hudnut and Lambert Pharmacal. The company was headquartered in Morris Plains, New Jersey, and was heavily invested in research and development, particularly in the fields of cardiovascular and metabolic diseases.

Elmer Holmes Bobst was a well-known figure in the pharmaceutical industry, having earned a reputation as a successful executive and business strategist. In 1945, he took on the challenge of turning around the struggling William R. Warner Company, a small pharmaceutical and cosmetic concern with a long history dating back to 1856. Despite the surprise of many, Bobst had a vision for the company and was determined to make it a major player in the industry.

Some of the most well-known trademarks in Warner-Lambert's portfolio were Listerine mouthwash, Sudafed cold and allergy medicine, and Lipitor, a cholesterol-lowering drug. Lipitor was one of the company's most profitable medicines, grossing billions of dollars every year and becoming the best-selling medication of all time.

2. SWOT Analysis

Name: Pfizer

Strengths	**Weaknesses**
1. Pfizer had a comprehensive product portfolio, with strong brands like Viagra and Lipitor, allowing the corporation to appeal to a wide spectrum of clients. 2. Pfizer had a reputation for having outstanding research and development skills, notably in the fields of cancer and immunology, with a considerable amount of sales spent on R&D. 3. Pfizer was in a great financial position, with a history of sustained sales growth and profitability, with a net income of $16.3 billion in 1999. 4. Pfizer has a significant worldwide footprint, with operations in more than 150 countries and a diverse income stream.	1. Pfizer success was highly dependent on a few major drugs, such as Lipitor, which accounted for a significant amount of the company's revenue. 2. Absence of new blockbuster products: Pfizer had seen a decrease in new product introductions in recent years, making it exposed to market shifts and greater competition. 3. Pfizer encountered regulatory issues, notably with medication approvals, which might delay or prohibit the launch of new medicines. 4. Pfizer faced public and media criticism for its pricing methods, notably in the United States, which might harm the company's brand and bottom line.
Opportunities	**Threats**
1. Pfizer had the chance to increase its footprint in emerging nations, where there was a growing demand for healthcare products and services. 2. Pfizer had the chance to create new drugs in fields such as cancer and immunology, which were seeing fast growth and innovation. 3. Pfizer had the chance to forge strategic agreements with other firms in order to develop new products and extend its distribution network. 4. Pfizer has the chance to invest in digital health technology and platforms to improve its services and patient outcomes.	1. Pfizer faced rising competition from other pharmaceutical companies, notably in the generics market. 2. Pfizer faced the possibility of important product patent expirations, which might result in revenue and market share losses, with the expiration of its Lipitor patent being a major issue. 3. Pfizer was under pressure to cut product prices, particularly in regions with strict government control, which might have an impact on the company's profits. 4. Pfizer's business operations included financial risks such as currency fluctuations, rising interest rates, and geopolitical instability, all of which might have an influence on the company's financial performance.

Name: Warner-Lambert

Strengths	**Weaknesses**
1. Warner-Lambert had a strong brand portfolio that included well-known brands such as Listerine and Schick razors, which helped the business retain a strong position in the consumer products industry. 2. Warner-Lambert had a good financial position, with a history of sustained sales growth and profitability, and a net income of $2.6 billion in 1999. 3. Warner-Lambert had a reputation for outstanding research and development skills, notably in the fields of cardiovascular illness and neurology, with a considerable amount of revenue spent on R&D. 4. Warner-Lambert had a significant global footprint, with operations in over 100 countries and a diverse income stream.	1. The success of Warner-Lambert was primarily reliant on a few major products, such as Lipitor, which accounted for a significant amount of the company's revenue. 2. Warner-Lambert has a limited presence in emerging markets, which might limit the company's development prospects in these regions. 3. Warner-Lambert encountered regulatory issues, notably about medication approvals, which might delay or prohibit the launch of new medicines. 4. Warner-Lambert faced public and media criticism for its marketing strategies, notably in the United States, which might harm the company's brand and bottom line.
Opportunities	**Threats**
1. Warner-Lambert saw an opportunity to extend its presence in emerging economies, where there was a growing demand for healthcare goods and services. 2. Warner-Lambert had the chance to create new goods in sectors such as cardiovascular illness and neurology, which were undergoing tremendous growth and innovation. 3. Warner-Lambert had the potential to build strategic alliances with other firms in order to develop new goods and extend its distribution network. 4. Warner-Lambert has the chance to engage in digital health technologies and platforms to expand its services and improve patient outcomes.	1. Warner-Lambert was facing increased rivalry from other pharmaceutical businesses, notably in the generics market. 2. Warner-Lambert faced the prospect of significant product patent expirations, which might result in revenue and market share losses, with the expiration of its Lipitor patent being a particular issue. 3. Warner-Lambert was under pressure to cut its product prices, particularly in regions with strict government control, which might have influenced the company's profitability. 4. Financial risks linked with Warner-business Lambert's activities included currency fluctuations, rising interest rates, and geopolitical insecurity, all of which might have an influence on the company's financial performance.

Technical Risk and Information Risk

One of the technical risks was related to the integration of the two companies' information technology (IT) systems. Pfizer and Warner-Lambert had different IT systems and processes, and integrating them was a complex and challenging task. This integration process created technical risks related to system compatibility, data accuracy, and operational disruptions. Another major risk that Pfizer faced was related to information security. The company's systems contained sensitive information about patients, research and development, financial information, and other confidential data. The merger increased the risk of data breaches and unauthorized access to this information.

3. Risk Identifications

Key Risk Indicators, or KRIs, are measures for evaluating and tracking risks related to a specific business process or transaction. Here are a few KRI examples for the combination of Pfizer and Warner-Lambert:

A. Positive Risk:

1. Increased profitability and revenue growth
2. Diversification of product

B. Negative Risk :

1. Increase in legal or regulatory violations
2. Integration delays or issues

A. Positive Risk:

1. **Increased profitability and revenue growth**

While rising profitability and revenue are frequently regarded as signals of successful integration, they can also cover up underlying problems or delays. For instance, there may be concerns about the integration's long-term viability if Pfizer was increasing revenue and profits by keeping the Warner-Lambert business unit distinct from the rest of the company. While greater profitability and revenue growth may be advantageous results of a merger, they should be weighed against any inherent risks and weaknesses they can introduce. It's also possible to reduce these problems and guarantee the long-term survival of the merged organization by tracking these parameters over time and taking proactive steps to resolve potential dangers. On the other hand, Competition may increase as profitability and sales increase, especially if Pfizer's success is reliant on a single product or market. Risks associated with market saturation, and pricing pressures, thethey must make significant investments in R&D to preserve competitiveness might result from this.

2. Diversification of product

Pfizer and Warner-Lambert were both significantly reliant on a select few important goods prior to the merger. Risks including the danger of patent expiry, regulatory changes, and market rivalry were more vulnerable by this risk concentration. By combining their respective product portfolios, the combined company was able to distribute risk across a wider variety of goods, so lowering its reliance on any good or market. Diversification across product lines also reduced sensitivity to outside influences including shifting market demand, competitive challenges, and governmental

changes. The combined company was better equipped to adapt to changes in the external environment since it had a variety of goods. The product portfolio diversity helped the combined company become more resilient and market-change-adaptive. The firm was better able to survive any unforeseen interruptions or market upheavals by having a variety of products. The combined firm was able to spread the risk and increase its overall resilience and adaptability to market changes thanks to the positive risk diversification of its product following the merger. Also, it enabled the business to boost its overall competitiveness and market share.

B. Negative Risk :

1. **Increase in legal or regulatory violations**

Significant fines and penalties may indeed be imposed for breaking laws or regulations, which might harm the combined entity's financial performance. This can lower profitability and make it more difficult for the business to engage in R&D or seek other growth prospects. Legal or regulatory infractions can potentially cause serious reputational harm, which can harm the combined entity's brand image. Reduced investor confidence, trouble hiring top talent, and decreasing consumer loyalty can all result from this. Integration issues for the combined business might also result from legal or regulatory infractions. For instance, it could be difficult to integrate the culture, beliefs, and operational procedures of one of the enterprises with those of the other if it has a history of breaking the law or other regulations. This may result in misunderstandings between cultures, high staff churn, and trouble creating appropriate synergies.

4. Qualitative Risk

A risk assessment that is based on individual opinions or in-depth research is known as qualitative risk. It entails a qualitative assessment of the probability and potential consequences of a risk event happening. Qualitative risk assessments can be useful in identifying possible hazards and their overall impact on a project or organization. They are frequently employed when data is scarce or when the risks are poorly understood.

A brainstorming session with stakeholders is frequently used in qualitative risk assessments to uncover prospective hazards as well as their likelihood and effect. The dangers are then ranked in order of importance based on their seriousness and chance of occurring. A qualitative risk assessment's objective is to identify possible hazards and create a plan to manage them before they materialize into significant issues.

Risk identification checklists, risk probability and effect assessment matrices, and risk heat maps are a few of the often-employed techniques in qualitative risk assessments. Although qualitative risk assessments can be helpful in identifying and prioritizing hazards, they might not offer a deep understanding of each risk's likelihood and consequences. As a result, quantitative risk evaluations should be included wherever practical.

5. Heatmap Methodology

In a heat map, different levels of intensity or concentration are depicted graphically using color. A risk heat map is a tool used to illustrate and convey the amount of risk associated with various events or scenarios in the context of risk management. Start by determining the hazards connected

to a project or company. Brainstorming sessions, risk analyses, or other risk management procedures can be used to do this.

Establish the standards for rating and ranking hazards. For instance, the possibility and possible consequences of any risk might be included in the criterion. Based on the risk criteria, give each risk a score. A color-coded scale, such as green, yellow, and red, or a numerical scale, such as 1 to 10, may be used to determine the scores. Create a heat map using a graphical tool, with the x-axis showing the risk's chance of happening and the y-axis representing its possible impact. The heat map is then used to illustrate the risk scores, with the brightest colors denoting the greatest risk ratings. Determine the most important hazards by analyzing the heat map and ranking them for risk management action. When presenting risk information to stakeholders, such as CEOs, project managers, and other team members, risk heat maps may be a useful tool. They can help in decision-making about risk management tactics and assist to concentrate attention on the most important hazards.

Fig1. Heat Map Risk Matrix

Impact of Risk : defined as the impact to the firm before the controls. (Inherent risk)	Increased profitability and revenue growth	Diversification of product	Increase in legal or regulatory violations
High	Changes in reimbursement policies affecting drug prices	The negative impact of product recalls or safety concerns; Failure to successfully develop and launch new products	Non-compliance with FDA regulations; Product liability lawsuits
Medium	Failure to meet revenue targets; Negative impact of economic conditions on sales	Regulatory approval delays for new products	Violations of anti-bribery laws
Low	Increased competition from other pharmaceutical companies	Failure to effectively market new products	Intellectual property disputes

5.1 Heatmap Assessment

Assign risk scores: Based on the identified risks and risk criteria, we can assign scores to each risk:

Risk 1: Increased profitability and revenue growth:

- Failure to meet revenue targets (Medium)
- Negative impact of economic conditions on sales (Medium)

- Changes in reimbursement policies affecting drug prices (High)
- Increased competition from other pharmaceutical companies (Low)

Risk 2: Diversification of product:

- Failure to successfully develop and launch new products (High)
- Regulatory approval delays for new products (Medium)
- Failure to effectively market new products (Low)
- Negative impact of product recalls or safety concerns (High)

Risk 3: Increase in legal or regulatory violations:

- Non-compliance with FDA regulations (High)
- Violations of anti-bribery laws (Medium)
- Product liability lawsuits (High)
- Intellectual property disputes (Low)

Many risks relating to increased profitability and revenue growth, product diversification, and a rise in legal or regulatory infractions have been highlighted as part of our risk assessment for Pfizer and Warner-Lambert. Based on our risk criteria, have given each of these dangers a risk score to better comprehend the potential effects.

Identified several risks that could influence Pfizer and Warner Lambert's financial performance in relation to increased profitability and revenue growth, including the failure to meet revenue targets, a negative impact of economic conditions on sales, adjustments to reimbursement policies that have an impact on drug prices, and increased competition from other pharmaceutical companies. Based on the possible severity of each danger, a risk score has been assigned.

Discovered many hazards associated with the creation, regulatory approval, and commercialization of new goods in terms of product diversification. These risks include the inability to create and introduce new goods successfully, delays in receiving regulatory permission for new products, a failure to properly market new products, and the detrimental effects of product recalls or safety issues. Based on the possible severity of each danger, a risk score has also been assigned.

Finally, identified several hazards connected to an increase in legal or regulatory infractions, such as FDA regulation non-compliance, anti-bribery legislation violations, product liability claims, and intellectual property issues. Based on the possible legal and reputational effects may have on Pfizer and Warner-Lambert, these hazards have been given risk ratings.

6. Quantitative Risk

Quantitative risk is a numerical representation of a given risk's probability and probable consequences. It entails calculating the likelihood that a risk will occur, as well as any possible effects it could have on a project or organization. Prioritizing and managing risks properly are made easier as a result.

The likelihood and effect of certain hazards are quantified using statistical methods and models in quantitative risk analysis. It entails estimating the likelihood of occurrence and the anticipated financial impact of a risky event using data. Techniques like Monte Carlo simulations, decision trees, and sensitivity analysis can be used to achieve this.

There are various indicators that can be used in quantitative analysis to evaluate the financial performance of companies such as Pfizer and Warner-Lambert. Here are some examples:

1. Price-to-Earnings (P/E) Ratio: The P/E ratio is a measure of valuation that contrasts the share price of a firm with its earnings per share. Investors are more likely to pay more for every dollar of earnings when the P/E ratio is greater. Warner-Lambert had a P/E ratio of 32.9 in 2000 compared to 28.5 for Pfizer. This shows that investors valued Warner-earnings Lamberts at a higher rate than Pfizer's earnings did.

2. Return on Equity (ROE): ROE measures the amount of net income returned as a percentage of shareholders' equity. A higher ROE indicates that a company is more efficient at generating profits with the shareholder's money. In 2000, Warner-Lambert had a higher ROE of 39.2% compared to Pfizer's ROE of 27.7%. This suggests that Warner-Lambert was generating higher profits per dollar of shareholders' equity.

3. Gross Profit Margin: By measuring the percentage of revenue left over after subtracting the cost of products sold, the gross profit margin (GPM), a financial indicator, gauges a company's profitability (COGS). With Pfizer's GPM at 82.5% and Warner Lambert's GPM at 82.8%, both businesses had high GPMs in the context of the 2000 merger between Pfizer and Warner-Lambert.

4. Debt-to-Equity Ratio: The debt-to-equity ratio calculates how much debt a business has in comparison to its equity. A corporation is more likely to rely on debt financing if its debt-to-equity ratio is larger, which might raise the financial risk. In comparison to Warner-Lambert, Pfizer had a lower debt-to-equity ratio in 2000 (0.26 vs. 0.74). This shows that Pfizer had a stronger financial position and was less dependent on loan funding.

7. Risk Response Strategy

In general, these metrics shed light on Pfizer and Warner-financial Lambert's situation and performance in 2000. Warner-Lambert had a better ROE, suggesting that it was making more money per dollar of equity, even though Pfizer had a greater market share and produced more sales. Investors appeared to be prepared to pay more per dollar of Warner profits, Lambert's according to the P/E ratio. Finally, the debt-to-equity ratio showed that Pfizer was in a better financial situation than Warner-Lambert.

Risk Mitigation Matrix:

Indicator	**Pfizer**	**Warner-Lambert**
Price to Earnings Ratio (P/E)	28.5	32.9
Return on Equity(ROE)	27.7%	39.2%
Gross Profit Margin	82.5%	82.8%
Debt-to-Equity Ratio	0.26	0.74

The risk response strategy for Pfizer and Warner-Lambert acquisition included a combination of risk mitigation, risk transfer, risk avoidance, and risk acceptance strategies. Here are some examples of the strategies used:

1. Risk Mitigation: Pfizer and Warner-Lambert identified the risks associated with the acquisition and implemented various measures to mitigate them. These included conducting thorough due diligence, integrating the companies' operations and systems, and aligning the culture and values of the two organizations.

Risk Transfer: The companies also used risk transfer strategies, such as purchasing insurance policies, to cover any unforeseen risks that may arise during and after the acquisition process. For example, they may have purchased liability insurance to protect against any legal claims that may arise.

2. Risk Avoidance: Pfizer and Warner-Lambert may have avoided certain risks altogether by not pursuing the acquisition or modifying the terms of the deal to minimize the risks involved.

Risk Acceptance: Finally, Pfizer and Warner-Lambert accepted certain risks as part of the acquisition process. For example, they may have accepted the risk that the acquisition may not generate the expected financial benefits or that some key employees may leave the company.

8. Key Risk Indicators (KRIs)

Key Risk Indicators (KRIs) are specific metrics or indicators that help in identifying the potential risks and uncertainties that may affect an organization's objectives. In the case of the Pfizer and Warner-Lambert merger acquisition in 2000, some of the key KRIs and their trigger points for action can be identified as follows:

1. Financial performance: The financial performance of both Pfizer and Warner-Lambert was a critical KRI during the merger process. The trigger points for action included a decrease in revenue, profit margins, or return on investment below the projected levels.

Integration and restructuring: The integration and restructuring process during the merger was important for KRIs. The trigger points for action included delays in the integration process, unexpected costs related to the merger, or employee retention issues.

2. Regulatory compliance: Regulatory compliance was another crucial KRI during the merger. The trigger points for action included regulatory fines, negative publicity related to regulatory compliance, or delays in the regulatory approval process.

Intellectual property: The management of the intellectual property was a significant KRI during the merger. The trigger points for action included disputes related to intellectual property, legal challenges related to patent infringement, or loss of key patents.

3. Customer satisfaction: Customer satisfaction was an important KRI during the merger. The trigger points for action included decreased customer satisfaction levels, increased customer complaints, and a decline in market share.

By monitoring these key risk indicators and their trigger points, Pfizer and Warner-Lambert could take appropriate action to mitigate the risks and uncertainties associated with the merger acquisition in 2000.

8. Monitoring and Control Risk

In the Pfizer and Warner acquisition and merger in 2000, there were several monitoring and control risks that could have had an impact on the success of the merger. Some of the key monitoring and control risks in this case included:

1. Integration of systems and processes: When two large companies merge, there is a risk that their systems and processes may not integrate seamlessly. This can result in delays, errors, and other problems. To mitigate this risk, Pfizer and Warner had to carefully plan and execute the integration of their systems and processes.

2. Cultural differences: Pfizer and Warner had different corporate cultures, and there was a risk that these cultural differences could cause problems during the merger. To address this risk, the companies had to work together to identify and address any cultural differences and to promote a shared vision and mission for the new company.

3. Regulatory compliance: Mergers and acquisitions are subject to regulatory scrutiny, and there is a risk that the companies may not comply with all relevant regulations. To mitigate this risk, Pfizer and Warner had to carefully review and comply with all relevant regulations and work closely with regulators to ensure a smooth transition.

To manage these and other monitoring and control risks, Pfizer and Warner likely had a comprehensive risk management plan in place, which included regular monitoring and review of key risk indicators, as well as contingency plans to address any issues that arose.

Conclusion

Based on the information provided earlier, the Pfizer and Warner-Lambert merger in 2000 was primarily focused on expanding Pfizer's product portfolio and global reach, as well as gaining access to Warner-Lambert's key products, including Lipitor. The merger posed several risks, including financial risks due to the high acquisition cost and integration challenges, as well as operational risks due to cultural differences and regulatory compliance.

To manage these risks, Pfizer and Warner-Lambert implemented several strategies, such as risk assessments, risk response strategies, and monitoring and control processes. The companies also focused on maintaining open communication and transparency throughout the merger process to ensure smooth integration.

Generally, the successful merger resulted in significant financial gains for Pfizer and established it as a major player in the pharmaceutical industry. The risk management and response plan implemented by Pfizer and Warner-Lambert allowed the companies to effectively traverse the risks associated with the merger and achieve long-term success through rigorous planning, market analysis, and risk management measures.

The key product of the merger was Lipitor, a cholesterol-lowering medication that became one of Pfizer's best-selling products. The successful integration of Lipitor into Pfizer's product portfolio was a significant contributor to the financial gains resulting from the merger.

References:

[1] Emerging from the Merger: Warner-Lambert and Pfizer
https://www.pharmaceuticalonline.com/doc/emerging-from-the-merger-warner-lambert-and-p-0001#:~:text=The%20merger%20between%20Warner-Lambert%20and%20Pfizer%20will%20produce,which%20will%20generate%20sales%20of%20over%20%242%20billion.
[2] Largest pharmaceutical M&A deals ever until 2022 Mikulic
https://www.statista.com/statistics/518674/largest-mergers-acquisitions-pharmaceutical/
[3] Pfizer's Warner-Lambert Acquisition Has Side Effects Herper
https://www.forbes.com/2000/06/21/mu5.html?sh=570c5cbb4614
[4] Acquisitions by Pfizer: Integrated Case Studies | Request PDF
This $90-billion merger deal resulted in the creation of the second-largest pharmaceutical company in the world. The deal ended the 3-month hostile battle to acquire Warner–Lambert. On merger...
https://www.researchgate.net/.../329325457_Acquisitions_by_Pfizer_Integrated_Case_Studies
[5] https://www.ftc.gov/sites/default/files/documents/cases/2000/07/pfizerwarnerlambertdo.htm
[6] How to Create a Risk Heatmap in Excel - Part 2 Caldas
https://riskmanagementguru.com/create-risk-heatmap-excel-part-2.html/#:~:text=%20How%20to%20Create%20a%20Risk%20Heatmap%20in,is%20to%20file%20in%20your%20risk...%20More%20
[7] How to use the risk assessment matrix to organize your project better Manager.
https://tms-outsource.com/blog/posts/risk-assessment-matrix/
[8] WARNER LAMBERT.
https://www.pfizer.com/about/history/pfizer_warner_lambert
[9] Pfizer, Warner-Lambert Ink Merger Deal - TheStreet
The new company's consumer products division will be based in Morris Plains, N.J., where Warner-Lambert is based. The combined company will have annual revenues of about $28 billion, including...
https://www.thestreet.com/investing/pfizer-warner-lambert-ink-merger-deal-878351
[10] Pfizer's Warner-Lambert Acquisition Has Side Effects
Herper
https://www.forbes.com/2000/06/21/mu5.html?sh=148355474614
[11] Buy-Side M&A Advisory Services: Mergers & Acquisitions
https://www.ey.com/en_us/strategy-transactions/buy-integrate?WT.mc_id=10818839&AA.tsrc=paidsearch&gclid=CjwKCAiAmJGgBhAZEiwA1JZolh3_0N0e7b2m0D1ANNawPtEbghaPFxORPf5L56JcCnd_UUEP9ax-PRoCcLkQAvD_BwE
[12] Risk Identification & Assessment - Merger/Acquisition - Powernoodle
https://www.powernoodle.com/models-article/merger-acquisition-risk-identification...
[13] 10 Most Common M&A Risks and Ways to Mitigate Them
https://dealroom.net/blog/mergers-and-acquisitions-transaction-risks-and-ways-to-mitigate-them